Pulmatrix Past Earnings Performance
Past criteria checks 0/6
Pulmatrix has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 3.6% per year.
Key information
2.5%
Earnings growth rate
60.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 3.6% |
| Return on equity | -78.5% |
| Net Margin | -193.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Pulmatrix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -14 | 7 | 0 |
| 30 Sep 23 | 7 | -16 | 7 | 0 |
| 30 Jun 23 | 7 | -18 | 7 | 0 |
| 31 Mar 23 | 6 | -18 | 7 | 0 |
| 31 Dec 22 | 6 | -19 | 7 | 0 |
| 30 Sep 22 | 5 | -22 | 7 | 0 |
| 30 Jun 22 | 4 | -25 | 7 | 0 |
| 31 Mar 22 | 5 | -24 | 7 | 0 |
| 31 Dec 21 | 5 | -23 | 6 | 0 |
| 30 Sep 21 | 7 | -19 | 6 | 16 |
| 30 Jun 21 | 10 | -21 | 6 | 16 |
| 31 Mar 21 | 11 | -19 | 6 | 16 |
| 31 Dec 20 | 13 | -19 | 7 | 16 |
| 30 Sep 20 | 12 | -20 | 7 | 0 |
| 30 Jun 20 | 9 | -13 | 7 | 0 |
| 31 Mar 20 | 11 | -20 | 9 | 0 |
| 31 Dec 19 | 8 | -21 | 8 | 0 |
| 30 Sep 19 | 6 | -21 | 8 | 0 |
| 30 Jun 19 | 5 | -22 | 8 | 0 |
| 31 Mar 19 | 0 | -20 | 7 | 0 |
| 31 Dec 18 | 0 | -21 | 8 | 0 |
| 30 Sep 18 | 0 | -21 | 8 | 0 |
| 30 Jun 18 | 0 | -20 | 8 | 0 |
| 31 Mar 18 | 0 | -20 | 8 | 0 |
| 31 Dec 17 | 0 | -18 | 8 | 0 |
| 30 Sep 17 | 0 | -23 | 8 | 0 |
| 30 Jun 17 | 0 | -22 | 7 | 0 |
| 31 Mar 17 | 0 | -26 | 7 | 0 |
| 31 Dec 16 | 1 | -28 | 8 | 0 |
| 30 Sep 16 | 1 | -23 | 8 | 0 |
| 30 Jun 16 | 2 | -24 | 9 | 0 |
| 31 Mar 16 | 1 | -30 | 10 | 0 |
| 31 Dec 15 | 1 | -26 | 10 | 0 |
| 30 Sep 15 | 1 | -6 | 8 | 0 |
| 30 Jun 15 | 1 | -13 | 6 | 0 |
| 31 Mar 15 | 0 | -5 | 4 | 0 |
| 31 Dec 14 | 0 | -6 | 3 | 0 |
| 31 Dec 13 | 1 | -13 | 3 | 0 |
Quality Earnings: 2PU is currently unprofitable.
Growing Profit Margin: 2PU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2PU is unprofitable, but has reduced losses over the past 5 years at a rate of 2.5% per year.
Accelerating Growth: Unable to compare 2PU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2PU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: 2PU has a negative Return on Equity (-78.47%), as it is currently unprofitable.